Oncopeptides AB

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: SE0009414576
SEK
5.25
-0.13 (-2.42%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Risky -

  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 255.88%, its profits have fallen by -1.7%
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

SEK 1,425 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-3.32

stock-summary
Return on Equity

-4,096.64%

stock-summary
Price to Book

218.01

Revenue and Profits:
Net Sales:
19 Million
(Quarterly Results - Jun 2025)
Net Profit:
-63 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.06%
0%
10.06%
6 Months
264.96%
0%
264.96%
1 Year
251.62%
0%
251.62%
2 Years
-8.66%
0%
-8.66%
3 Years
-55.47%
0%
-55.47%
4 Years
-18.63%
0%
-18.63%
5 Years
-95.38%
0%
-95.38%

Oncopeptides AB for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
129.44%
EBIT Growth (5y)
12.53%
EBIT to Interest (avg)
-546.33
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.91
Sales to Capital Employed (avg)
0.29
Tax Ratio
0.18%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-19.96
EV to EBIT
-5.24
EV to EBITDA
-5.24
EV to Capital Employed
-108.59
EV to Sales
27.30
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 44.36% vs 34.34% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -3.46% vs 27.22% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "19.20",
          "val2": "13.30",
          "chgp": "44.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-57.50",
          "val2": "-60.70",
          "chgp": "5.27%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.60",
          "val2": "0.80",
          "chgp": "725.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-62.80",
          "val2": "-60.70",
          "chgp": "-3.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,994.40%",
          "val2": "-4,573.40%",
          "chgp": "157.90%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -10.23% vs 319.05% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -14.25% vs 26.30% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "31.60",
          "val2": "35.20",
          "chgp": "-10.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-279.70",
          "val2": "-248.10",
          "chgp": "-12.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "12.70",
          "val2": "5.80",
          "chgp": "118.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-284.60",
          "val2": "-249.10",
          "chgp": "-14.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-9,146.90%",
          "val2": "-7,357.40%",
          "chgp": "-178.95%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
19.20
13.30
44.36%
Operating Profit (PBDIT) excl Other Income
-57.50
-60.70
5.27%
Interest
6.60
0.80
725.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-62.80
-60.70
-3.46%
Operating Profit Margin (Excl OI)
-2,994.40%
-4,573.40%
157.90%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 44.36% vs 34.34% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -3.46% vs 27.22% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
31.60
35.20
-10.23%
Operating Profit (PBDIT) excl Other Income
-279.70
-248.10
-12.74%
Interest
12.70
5.80
118.97%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-284.60
-249.10
-14.25%
Operating Profit Margin (Excl OI)
-9,146.90%
-7,357.40%
-178.95%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -10.23% vs 319.05% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -14.25% vs 26.30% in Dec 2023

stock-summaryCompany CV
About Oncopeptides AB stock-summary
stock-summary
Oncopeptides AB
Pharmaceuticals & Biotechnology
Oncopeptides AB is a Sweden-based clinical development pharmaceutical company, which is primarily engaged in the healthcare industry. The Company focuses on research and development of cancer treatment solutions. The Company's product Ygalo is a peptidase potentiated alkylator, a type of cytotoxic drug that is targeted for use in the treatment of multiple myeloma. Ygalo is an alkylating agent that leverages the overrepresentation of peptidase enzymes in cancer cells to rise the concentration of active cancer fighting molecules in myeloma cells. Ygalo is intended for the treatment of patients with late-stage relapsed and refractory multiple myeloma. Ygalo is administered intravenously and is transported into cells where it is cleaved by peptidase enzymes, which impair transport of its active cancer-fighting agents out of the cell at the same time as driving more Ygalo into the cell.
Company Coordinates stock-summary
Company Details
Luntmakargatan 46, van 7 , STOCKHOLM None : 111 37
stock-summary
Tel: 46 8 615204046 70 8537292
stock-summary
Registrar Details